Sandbox: sadaf: Difference between revisions

Jump to navigation Jump to search
Ssharfaei (talk | contribs)
Ssharfaei (talk | contribs)
No edit summary
 
(77 intermediate revisions by the same user not shown)
Line 1: Line 1:
== Differential Diagnosis ==
__NOTOC__
Different causes of the bleeding disorders can be differentiated based on their clinical manifestation and laboratory findings.


These features have discussed in the below table:
[[Sandbox: wdx]]
{|
 
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Category
[[Xyz]]
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Subcategory
 
! colspan="2" rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease
[[Abc]]
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |History
# [[Sandbox:Preeti]]
! colspan="6" align="center" style="background:#4479BA; color: #FFFFFF;" + |Clinical manifestation
# [[Lymphoma]]
! colspan="5" align="center" style="background:#4479BA; color: #FFFFFF;" + |Laboratory testing
# [[Breast lumps differential diagnosis]]
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Comments
# [[Neck masses differential diagnosis]]
# [[Leukemia]]
{| class="wikitable"
|+
|-
|-
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Mucosal bleeding
| colspan="2" |[[:Category:Risk calculator]]
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Petechia
[[Category:Risk calculator]]
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Ecchymoses
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Menorrhagia
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hematoma
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hemarthrosis
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Plt
! align="center" style="background:#4479BA; color: #FFFFFF;" + |BT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |PT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |PTT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |TT
|-
|-
! rowspan="16" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelet disorders
| colspan="2" |[[Deep vein thrombosis assessment of clinical probability and risk scores]]
! rowspan="7" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Thrombocytopenia]]
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Infection]]-Induced [[thrombocytopenia]]<span name="harr_c115s002s001s002p001"></span><span name="9100754"></span>
| align="left" style="background:#F5F5F5;" |
* History of prior infection
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | −
|-
|-
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Medication|Medications]]-Induced [[Thrombocytopenia|thrombocy]]<span name="harr_c115s002s001s003p001"></span><span name="9100757"></span>[[Thrombocytopenia|topenia]]
| colspan="2" |[[Pulmonary embolism assessment of clinical probability and risk scores]]
| align="left" style="background:#F5F5F5;" |
*History of [[Medication|medications]] such as:
** [[Furosemide]]
** [[Non-steroidal anti-inflammatory drug|Nonsteroidal anti-inflammatory drugs]] ([[Non-steroidal anti-inflammatory drug|NSAIDs]])
** [[Penicillin]]
** [[Quinidine]]
** [[Quinine]]
** [[Ranitidine]]
** [[Sulfonamide (medicine)|Sulfonamides]]
** [[Linezolid]]
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Most important part of treatment is discontinuing of the medication.
|-
|-
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Heparin-Induced Thrombocytopenia|Heparin-Induced thrombocytopenia]]<span name="harr_c115s002s001s004p001"></span><span name="9100761"></span>
|[[Padua prediction score]]
| align="left" style="background:#F5F5F5;" |
|[[widget:PaduaVTEscore]]
* [[Thrombosis]]
* Unexplained [[thrombocytopenia]] up to 3 weeks after the end of [[heparin]] therapy
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | For more information click here: [[Heparin-induced thrombocytopenia]].
|-
|-
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Idiopathic thrombocytopenic purpura|Immune Thrombocytopenic Purpura]] ([[Idiopathic thrombocytopenic purpura|ITP]])<span name="harr_c115s002s001s005p001"></span><span name="9100771"></span>
|[[IMPROVE risk score calculator]]
| align="left" style="background:#F5F5F5;" |
|[[Widget:IMPROVEScore]]
* History of prior [[infection]] or no history
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | −
|-
|-
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Inherited [[Thrombocytopenia]]<span name="harr_c115s002s001s006p001"></span><span name="9100783"></span>
|[[IMPROVEDD risk score calculator]]
| align="left" style="background:#F5F5F5;" |
|[[Widget:IMPROVEDDScore]]
* Positive family history
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | −
|-
|-
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Thrombotic thrombocytopenic purpura|Thrombotic Thrombocytopenic Purpura]] ([[Thrombotic thrombocytopenic purpura|TTP]])<span name="harr_c115s002s002s001p001"></span><span name="9100787"></span>
|[[Caprini score calculator]]
| align="left" style="background:#F5F5F5;" | History of:
|[[Widget:CapCal]]
*[[Cancer]]
*[[Bone marrow transplantation]]
*[[Pregnancy]]
*[[Medication]]
**[[Platelet]] aggregation inhibitors ([[ticlopidine]] and [[clopidogrel]])
**Immunosuppressants ([[cyclosporine]], [[mitomycin]], [[tacrolimus]]/FK506, [[interferon|interferon-α]])
*[[HIV-1]] infection
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | −
|-
|-
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Hemolytic-uremic syndrome|Hemolytic Uremic Syndrome]]<span name="harr_c115s002s002s002p001"></span><span name="9100796"></span>
|[[Wells score calculator for DVT]]
| align="left" style="background:#F5F5F5;" |History of:
|[[Widget:DVT Wells score calculator]]
* [[Infections]]
* [[Malignancy]], [[chemotherapy]], and [[ionizing radiation]]
* [[Calcineurin inhibitor]]s and [[transplantation]]
* [[Pregnancy]], [[HELLP syndrome]], and [[oral contraceptive pill]]
* [[Systemic lupus erythematosis]] 
* [[Antiphospholipid syndrome|Antiphospholipid antibody syndrome]]
* [[Glomerulopathy]]
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | −
|-
|-
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Subcategory
|[[Modified Wells score calculator for DVT]]
! colspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease
|[[Widget:DVT Modified Wells score calculator]]
! align="center" style="background:#4479BA; color: #FFFFFF;" + |History
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Mucosal bleeding
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Petechia
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Ecchymoses
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Menorrhagia
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hematoma
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hemarthrosis
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Plt
! align="center" style="background:#4479BA; color: #FFFFFF;" + |BT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |PT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |PTT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |TT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Comments
|-
|-
! align="center" style="padding: 5px 5px; background: #DCDCDC;" |Thromobcytosis
|[[Pulmonary embolism Wells score calculator]]
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Iron deficiency anemia|Iron deficiency anemia]]
|[[widget:PE_calculator]]
Inflammatory diseases
 
[[Splenectomy]]
 
[[Essential thrombocytosis|Essential thrombocytosis]]
| align="left" style="background:#F5F5F5;" |
* Digital [[pain]]
* [[Gangrene]]
* [[Erythromelalgia]]
* H[[eadache]]
* [[Paresthesia|Paresthesias]] 
* [[Transient ischemic attack|Transient ischemic attacks]]
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |±
| align="center" style="background:#F5F5F5;" |±
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | Nl or ↑
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | −
|-
|-
! rowspan="6" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Qualitative Disorders of [[Platelet]] Function<span name="harr_c115s002s004s001p001"></span><span name="9100803"></span>
|[[Pulmonary embolism modified Wells score calculator]]
! rowspan="4" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Inherited Disorders of [[Platelet]] Function<span name="harr_c115s002s004s001p001"></span><span name="9100803"></span>
|[[Widget:PE Modified Wells score calculator]]
! align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Glanzmann's thrombasthenia|Glanzmann’s thrombasthenia]]
| align="left" style="background:#F5F5F5;" |
* Positive family history
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | Rare
| align="center" style="background:#F5F5F5;" | Nl or ↓
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="left" style="background:#F5F5F5;" |
* AR inheritance
* Absence of the platelet Gp IIb/IIIa receptor
* Diminished for GP 2B-3A on [[Flow cytometry|flow cytometry]]  
|-
|-
! align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Bernard-Soulier syndrome]]
|[[AMUSE score calculator]]
| align="left" style="background:#F5F5F5;" |
|[[Widget:AMUSE_score_calculator]]
* Positive family history
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | Nl or ↓
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="left" style="background:#F5F5F5;" |
* AR inheritance
* Absence of the platelet Gp Ib-IX-V receptor
* On PBS: giant platelets
* Ristocetin - no aggregation
|-
|-
! align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Wiskott-Aldrich syndrome]]
|[[HAMILTON score calculator]]
| align="left" style="background:#F5F5F5;" |
|[[Widget:HAMILTON_score_calculator]]
* Positive family history
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | Nl or ↓
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="left" style="background:#F5F5F5;" |
* Anti-WASP antibody can be used to detect presence or absence of WAS protein
* In Wiskott–Aldrich syndrome, the [[Platelet|platelets]] are small and do not function properly. They are removed by the [[spleen]], which leads to low [[platelet]] counts.
|-
|-
! align="left" style="padding: 5px 5px; background: #DCDCDC;" |Platelet storage pool disorder:
|[[Geneva score calculator]]
*[[Hermansky-Pudlak syndrome]]
|[[Widget:Geneva_score_calculator]]
*[[Chediak-Higashi syndrome]]
*[[Gray platelet syndrome]]
| align="center" style="background:#F5F5F5;" |
* Positive family history
* [[Hairy cell leukemia]]
* [[Cardiovascular bypass]]
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | Nl or ↓
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="left" style="background:#F5F5F5;" |
* AD inheritance
* AbNlities of platelet granule formation
|-
|-
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Acquired Disorders of [[Platelet]] Function<span name="harr_c115s002s004s002p001"></span><span name="9100808"></span>
|[[Revised Geneva score calculator]]
| align="left" style="background:#F5F5F5 " |
|[[Widget:Revised_Geneva_score_calculator]]
* [[Chronic renal failure pathophysiology|Uremia]]
* [[Cardiopulmonary bypass]]
* Hematologic disorders such as: [[Myeloproliferative disease|myeloproliferative]] and [[Myelodysplastic syndrome|myelodysplastic syndromes]]
| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" |±
| align="center" style="background:#F5F5F5;" |±
| align="center" style="background:#F5F5F5;" | Nl or ↓
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | −
|-
|-
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Von Willebrand disease|Von Willebrand Disease]]<span name="harr_c115s002s005p001"></span><span name="9100810"></span>
|[[Simplified Geneva Score calculator]]
| align="left" style="background:#F5F5F5;" |
|[[Widget:Simplified_Geneva_score_calculator]]
* Easy bruising
* [[Epistaxis]]
* Oral cavity bleeding
* Bleeding after dental extraction/surgery
* [[Menorrhagia]]
* [[Postpartum hemorrhage]]
| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" |±
| align="center" style="background:#F5F5F5;" |±
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | See the table below for the details about different types.
|-
|-
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Subcategory
|[[TIMI Risk Score for Unstable Angina or NSTEMI]]
! colspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease
|[[Widget:TIMI_UA_NSTEMI]]
! align="center" style="background:#4479BA; color: #FFFFFF;" + |History
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Mucosal bleeding
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Petechia
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Ecchymoses
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Menorrhagia
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hematoma
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hemarthrosis
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Plt
! align="center" style="background:#4479BA; color: #FFFFFF;" + |BT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |PT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |PTT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |TT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Comments
|-
|-
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Vessel wall disorders
|[[TIMI Risk Score for STEMI]]
! align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Metabolism|Metabolic]] and [[Inflammation|Inflammatory]] Disorders
|[[Widget:TIMI_STEMI]]
! colspan="2"  align="left" style="padding: 5px 5px; background: #DCDCDC;" |
* Acute febrile illnesses
* [[Cryoglobulinemia|Mixed cryoglobulinemia]]
* [[Monoclonal gammopathy|Monoclonal gammopathies]]
* [[Rocky Mountain spotted fever]]
* [[Vitamin C deficiency]]
* [[Cushing's syndrome|Cushing’s syndrome]]  
* Chronic [[glucocorticoid]] therapy
* [[Vasculitis]] such as Henoch-Schönlein Purpura
| align="left" style="background:#F5F5F5;" |
* History of the underlying disease
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" |+
| align="center" style="background:#F5F5F5;" |+
| align="center" style="background:#F5F5F5;" |±
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |Nl or ↑
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |−
|-
|-
! align="center" style="padding: 5px 5px; background: #DCDCDC;" |Inherited Disorders of the [[Vessel wall|Vessel Wall]]
|[[Tygerberg score]]
! colspan="2" align="left" style="background:#DCDCDC;" |
|[[widget:Tygerberg_score]]
* [[Marfan's syndrome|Marfan’s syndrome]]
* [[Ehlers-Danlos syndrome]]
* [[Pseudoxanthoma elasticum]]
* [[Hereditary hemorrhagic telangiectasia]] ([[Hereditary hemorrhagic telangiectasia|HHT]], or [[Osler-Weber-Rendu|Osler-Weber-Rendu disease]])
| align="center" style="background:#F5F5F5;" |
* Positive family history
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" |+
| align="center" style="background:#F5F5F5;" |+
| align="center" style="background:#F5F5F5;" |±
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |Nl or ↑
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |−
|-
|-
! rowspan="15" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Coagulation factor disorders
|[[CHA2DS2-VASc Score]]
<ref name="pmid28966616" />
|[[Widget:CHA2DS2VASc]]
! align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Fibrinogen]] deficiency
! colspan="2" align="left" style="padding: 5px 5px; background: #DCDCDC;" |
Different types of the [[fibrinogen]] disorders:
* [[Fibrinogen#Congenital afibrinogenemia|Congenital afibrinogenemia]]
* [[Fibrinogen#Congenital hypofibrinogenemia|Congenital hypofibrinogenemia]]
* [[Fibrinogen#Fibrinogen storage disease|Fibrinogen storage disease]]
* [[Fibrinogen#Congenital dysfibrinogenemia|Congenital dysfibrinogenemia]]
* [[Fibrinogen#Hereditary fibrinogen A.CE.B1-Chain amyloidosis|Hereditary fibrinogen Aα-Chain amyloidosis]]
* [[Fibrinogen#Acquired dysfibrinogenemia|Acquired dysfibrinogenemia]]
| align="left" style="background:#F5F5F5;" |
* [[Epistaxis]]
* Easy [[Bruise|bruising]]
* [[Menorrhagia]]
* [[Muscle]] bleeds
* [[Hemarthrosis]]
* [[Bleeding]] from the [[umbilical cord]] stump after birth
* Bleeding after [[dental surgery]] or tooth extraction
* AbNl bleeding during or after injury, surgery, or childbirth
* [[Gastrointestinal tract|Gastrointestinal]] [[hemorrhage]]
* [[Cerebral hemorrhage]]
* [[Thrombosis]]
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" |+
| align="center" style="background:#F5F5F5;" |+
| align="center" style="background:#F5F5F5;" |±
| align="center" style="background:#F5F5F5;" |+
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↑
| align="left" style="background:#F5F5F5;" |
* Impaired fibrin cross-linking or clot dissolution
* Mild or severe bleeding idepend on levels of functional fibrinogen
* Variable age of onset
|-
|-
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Subcategory
|[[CHADS2 score]]
! colspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease
|[[Widget:CHADS2score]]
! align="center" style="background:#4479BA; color: #FFFFFF;" + |History
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Mucosal bleeding
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Petechia
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Ecchymoses
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Menorrhagia
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hematoma
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hemarthrosis
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Plt
! align="center" style="background:#4479BA; color: #FFFFFF;" + |BT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |PT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |PTT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |TT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Comments
|-
|-
! colspan="3" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Prothrombin deficiency]]
|[[HAS-BLED score]]
|
|[[Widget:HASBLEDscore]]
* Easy [[bruising]]
* [[Epistaxis]]
* Soft-tissue hemorrhage
* Excessive postoperative bleeding
* [[Menorrhagia]]
* Muscle [[Hematoma|hematomas]]
* [[Hemarthrosis]]
* [[Intracranial hemorrhage|Intracranial]] bleeding
|−
|<nowiki>+</nowiki>
|<nowiki>+</nowiki>
|<nowiki>+</nowiki>
|<nowiki>+</nowiki>
|<nowiki>+</nowiki>
|Nl
|Nl
|↑
|↑
|↑
|−
|-
|-
! colspan="3" rowspan="1" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Factor V deficiency]]
|[[The GRACE risk score]]
|
|[[Widget:GRACEscore]]
* Excessive bruising with minor injuries
* [[Epistaxis]]
* [[Hemarthrosis]]
* [[Menorrhagia]]
* [[Intracerebral hemorrhage|Intracerebral hemorrhages]]
* [[Pulmonary hemorrhage]]  
|−
|_
|<nowiki>+</nowiki>
|<nowiki>+</nowiki>
| +
| +
|Nl
|↑
|↑
|↑
|Nl
|The severity of bleeding is only partly related to the degree of factor V deficiency. Some patients with undetectable plasma levels of factor V experience only relatively mild bleeding.
|-
|-
! colspan="3" rowspan="1" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Factor VII deficiency]]
|
|
* Easy [[Bruise|bruising]]
* Mucosal bleeding
* Postoperative bleeding
* [[Menorrhagia]]
* Soft tissue hematomas
* [[Thrombosis]]
|
|
|-
|[[Ranson criteria]]
[[Acute pancreatitis diagnostic criteria]]
|[[Widget:RansonScore]]
|-
|[[Apgar score]]
|[[Widget:Apgarscore]]
|-
|[[Glasgow coma scale]]
|[[Widget:Adult_GCS]]
|-
|[[Pediatric Glasgow Coma Scale]]
|[[Widget:PGCS]]
|-
|[[Cincinnati stroke scale]]
|[[Widget:Cincinnati_Stroke_Scale]]
|-
|[[DIPSS Plus Score]]
|[[Widget:DIPSS_Plus_Score]]
|-
| colspan="2" |[[ICU scoring systems]]
|-
|[[APACHE II]]
|[[Widget:APACHEII]]
|-
|[[SAPS II]]
|[[Widget:SAPSII]]
|-
|[[SAPS III]]
|[[Widget:SAPSIII]]
|-
|[[PIM2]]
|
|
|
|}
|<nowiki>+</nowiki>
==Table==
| +
{|
| +
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Complications
|Nl
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Polymyositis
|
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Dermatomyositis
|
|Nl
|Nl
|Thrombosis occurs in inherited factor VII deficiency  most cases are associated with the administration of factor VII replacement therapy
|-
|-
! colspan="3" rowspan="1" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Factor X deficiency]]
! align="center" style="background:#DCDCDC;" + |[[Cancer|Malignancy]]
|
| align="left" style="background:#F5F5F5;" + |
* Prolonged bleeding following circumcision
*[[Lung]]
| align="left" style="background:#F5F5F5;" + |
*[[Lung]]
|}
<br>
===Calculation of the Padua Prediction Score===
Shown below is a calculator using the predictive score for VTE among hospitalized medical patients. Check all boxes that apply to your patient:


* Easy [[Bruise|bruising]]
{| style="border: 0; float: left; width: 45%; position: float; background: #104E8B; border-radius: 10px 10px 10px 10px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5); margin: 0 0 0 0; padding: 5px 5px; font-weight: bold;"
* [[Hematuria]]
| colspan="2" style="text-align: center; color: #FFFFFF; font-size: 120%;" | IMPROVE Bleeding Risk Score
* [[Menorrhagia]]
|-
* Abortion
! style=" text-align: left; color: #4479BA; background: #FFFFFF; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 0 0 rgba(0, 0, 0, 0.2); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |Variable
* Postpartum hemorrhage
! style=" text-align: center; color: #4479BA; background: #FFFFFF; border-radius: 5px 5px 5px 5px; text-shadow: 0 0 0 rgba(0, 0, 0, 0.2); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |Score
* Epistaxis
|-
* Pseudotumors
! style=" text-align: left; color: #FFFFFF; background: #4479BA; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |Active gastric or duodenal ulcer
* Intracranial bleeding
| style=" text-align: center; color: #FFFFFF; background: #4479BA; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |4.5
* Hemarthroses
|-
|
! style=" text-align: left; color: #FFFFFF; background: #4479BA; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |Prior bleeding within the last 3 months
|<nowiki>+</nowiki>
| style=" text-align: center; color: #FFFFFF; background: #4479BA; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |4
| +
|-
| +
! style=" text-align: left; color: #FFFFFF; background: #4479BA; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |Thrombocytopenia (<50x10<sup>9</sup>/L)
| +
| style=" text-align: center; color: #FFFFFF; background: #4479BA; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |4
| +
|-
|Nl
! style=" text-align: left; color: #FFFFFF; background: #4479BA; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |Age ≥ 85 years
|Nl
| style=" text-align: center; color: #FFFFFF; background: #4479BA; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |3.5
|↑
|↑
|Nl
|
|-
|-
! colspan="3" rowspan="1" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Factor XII|Factor XII deficiency]]
! style=" text-align: left; color: #FFFFFF; background: #4479BA; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |Liver failure (INR>1.5)
|
| style=" text-align: center; color: #FFFFFF; background: #4479BA; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |2.5
* Majority,asymptomatic
* Recurrent miscarriages
* Painful leg ulcers
|
|_
|_
|_
|_
|_
|Nl
|Nl
|Nl
|↑
|Nl
|
|-
|-
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Subcategory
! style=" text-align: left; color: #FFFFFF; background: #4479BA; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |Severe kidney failure (GFR< 30 mL/min/m<sup>2</sup>)
! colspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease
| style=" text-align: center; color: #FFFFFF; background: #4479BA; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |2.5
! align="center" style="background:#4479BA; color: #FFFFFF;" + |History
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Mucosal bleeding
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Petechia
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Ecchymoses
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Menorrhagia
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hematoma
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hemarthrosis
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Plt
! align="center" style="background:#4479BA; color: #FFFFFF;" + |BT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |PT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |PTT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |TT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Comments
|-
|-
! colspan="3" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[High-molecular-weight kininogen|High molecular weight kininogen (HMWK)]] deficiency
! style=" text-align: left; color: #FFFFFF; background: #4479BA; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |Admission to ICU or CCU
|
| style=" text-align: center; color: #FFFFFF; background: #4479BA; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |2.5
* Possibility of positive family history of bleeding
|
|_
|_
|_
|_
|_
|Nl
|Nl
|Nl
|↑
|Nl
|
|-
|-
! colspan="3" rowspan="1" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Prekallikrein]] deficiency
! style=" text-align: left; color: #FFFFFF; background: #4479BA; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |Central venous catheter
|
| style=" text-align: center; color: #FFFFFF; background: #4479BA; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |2
* Possibility of positive family history of bleeding
|
|_
|_
|_
|_
|_
|Nl
|Nl
|Nl
|↑
|Nl
|
|-
|-
! rowspan="1" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Factor XIII deficiency]]
! style=" text-align: left; color: #FFFFFF; background: #4479BA; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |Rheumatic disease
! colspan="2" |
| style=" text-align: center; color: #FFFFFF; background: #4479BA; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |2
* Sub unit A mutation disease (more common)
* Sub unit B mutation disease
|
* Possibility of positive family history of bleeding
|Nl
|Nl
|Nl or ↑
|Nl
|Nl
|
* Impaired fibrin cross linking or clot dissolution
* The severity of factor XIII deficiency bleeds can be different in different patients
|-
|-
! rowspan="3" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Hemophilia]]
! style=" text-align: left; color: #FFFFFF; background: #4479BA; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |Active malignancy
 
| style=" text-align: center; color: #FFFFFF; background: #4479BA; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |2
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Type A deficiency
|
* Eeasy [[Bruise|bruising]]
* Inadequate clotting in [[trauma]] or mild injury
* Spontaneous hemorrhage
* [[Hemarthrosis]]
* [[Epistaxis]]
* [[Gingival bleeding]]
| −
| −
| −
| +
| +
|<nowiki>+</nowiki>
|Nl
|Nl
|Nl
|↑
|Nl
|−
|-
|-
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Type B deficiency
! style=" text-align: left; color: #FFFFFF; background: #4479BA; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |Age: 40-84 years
|
| style=" text-align: center; color: #FFFFFF; background: #4479BA; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |1.5
* Neonatal bleeding
* Trauma-related soft-tissue hemorrhage
* [[Hemarthrosis]] 
* [[Hematoma|Hematomas]]
| −
| −
| −
|<nowiki>+</nowiki>
| +
|<nowiki>+</nowiki>
|Nl
|Nl
|Nl
|↑
|Nl
|
|-
|-
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Type C deficiency
! style=" text-align: left; color: #FFFFFF; background: #4479BA; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |Male
|
| style=" text-align: center; color: #FFFFFF; background: #4479BA; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |1
* Family history
* Bleeding after surgery or injury
| −
| −
| −
|<nowiki>+</nowiki>
|Rare
|Rare
|Nl
|Nl
|Nl
|↑
|Nl
| −
|-
|-
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Subcategory
! style=" text-align: left; color: #FFFFFF; background: #4479BA; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |Moderate kidney failure (GFR: 30-59 mL/min/m<sup>2</sup>)
! colspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease
| style=" text-align: center; color: #FFFFFF; background: #4479BA; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |1
! align="center" style="background:#4479BA; color: #FFFFFF;" + |History
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Mucosal bleeding
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Petechia
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Ecchymoses
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Menorrhagia
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hematoma
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hemarthrosis
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Plt
! align="center" style="background:#4479BA; color: #FFFFFF;" + |BT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |PT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |PTT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |TT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Comments
|-
|-
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Rare diseases
! colspan="2" style=" text-align: left; color: #4479BA; background: #FFFFFF; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 0 0 rgba(0, 0, 0, 0.2); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |Result:
! colspan="3" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Disseminated intravascular coagulation|Disseminated Intravascular Coagulation]]
!
* [[Trauma]]
* Burn
* [[Crush injury]]
* [[Sepsis]]
* [[Malignancy]]
* Obstetric complication: abruption, amniotic fluid embolism
* [[Hemolytic anemia]]
|<nowiki>+</nowiki>
| +
|<nowiki>+</nowiki>
| +
|<nowiki>+</nowiki>
|<nowiki>+</nowiki>
|↓
|↑
|↑
|↑
|Nl
| −
|-
|-
! colspan="3" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Vitamin K Deficiency]]
! colspan="2" style=" text-align: left; color: #4479BA; background: #FFFFFF; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 0 0 rgba(0, 0, 0, 0.2); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |Interpretation:
!
* Bleeding after trauma
* [[Epistaxis]]
* [[Hematoma]]
* Gastrointestinal bleeding
* [[Menorrhagia]]
* [[Hematuria]]
* Gum bleeding
* Oozing from venipuncture sites
* Easy [[Bruise|bruisability]]
|<nowiki>+</nowiki>
| −
| +
| +
|<nowiki>+</nowiki>
|<nowiki>+</nowiki>
|Nl
|↑
|↑
|Nl or mildly prolonged
|Nl
| −
|}
|}
Different types of Von-Willebrand diseases can be differentiated from each other based on the following table:
<br style="clear:left" />
 
===Calculation of the test Prediction Score===
Shown below is a calculator using the predictive score for VTE among hospitalized medical patients. Check all boxes that apply to your patient:


{|
{| style="border: 0; float: left; width: 45%; position: float; background: #104E8B; border-radius: 10px 10px 10px 10px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5); margin: 0 0 0 0; padding: 5px 5px; font-weight: bold;"
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Type of VWD
| colspan="2" style="text-align: center; color: #FFFFFF; font-size: 120%;" | IMPROVE Bleeding Risk Score
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Type of factor deficiency
|-
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Prevalence
! style=" text-align: left; color: #4479BA; background: #FFFFFF; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 0 0 rgba(0, 0, 0, 0.2); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |Variable
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Inheritance pattern
! style=" text-align: center; color: #4479BA; background: #FFFFFF; border-radius: 5px 5px 5px 5px; text-shadow: 0 0 0 rgba(0, 0, 0, 0.2); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |Score
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Clinical manifestations
|-
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |VWF activity
! rowspan="2" style=" text-align: left; color: #FFFFFF; background: #4479BA; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |Gender
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |RIPA
| style=" text-align: center; color: #FFFFFF; background: #4479BA; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |Female
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Factor VIII
|-
| style=" text-align: center; color: #FFFFFF; background: #4479BA; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |Male
|-
! rowspan="4" style=" text-align: left; color: #FFFFFF; background: #4479BA; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |Age
| style=" text-align: center; color: #FFFFFF; background: #4479BA; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |0-70
|-
| style=" text-align: center; color: #FFFFFF; background: #4479BA; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |71-80
|-
| style=" text-align: center; color: #FFFFFF; background: #4479BA; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |81-90
|-
| style=" text-align: center; color: #FFFFFF; background: #4479BA; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |>90
|-
! rowspan="5" style=" text-align: left; color: #FFFFFF; background: #4479BA; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |Hgb ('''g/dL)'''
| style=" text-align: center; color: #FFFFFF; background: #4479BA; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |>17 '''g/dL'''
|-
| style=" text-align: center; color: #FFFFFF; background: #4479BA; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |15.5-17 '''g/dL'''
|-
| style=" text-align: center; color: #FFFFFF; background: #4479BA; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |12.5-15.5 '''g/dL'''
|-
| style=" text-align: center; color: #FFFFFF; background: #4479BA; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |12.5-11 '''g/dL'''
|-
| style=" text-align: center; color: #FFFFFF; background: #4479BA; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |<11 '''g/dL'''
|-
! rowspan="2" style=" text-align: left; color: #FFFFFF; background: #4479BA; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |CrCl (mL/min)
| style=" text-align: center; color: #FFFFFF; background: #4479BA; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |30-60 mL/min
|-
| style=" text-align: center; color: #FFFFFF; background: #4479BA; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |15-30 mL/min
|-
! rowspan="2" style=" text-align: left; color: #FFFFFF; background: #4479BA; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |Albumin
| style=" text-align: center; color: #FFFFFF; background: #4479BA; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |>3.5 g/dL
|-
| style=" text-align: center; color: #FFFFFF; background: #4479BA; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |≤3.5 g/dL
|-
! rowspan="2" style=" text-align: left; color: #FFFFFF; background: #4479BA; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |D-dimer
| style=" text-align: center; color: #FFFFFF; background: #4479BA; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |≥1 µg/mL
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" |Type 1
| style=" text-align: center; color: #FFFFFF; background: #4479BA; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |<1 µg/mL
| align="center" style="background:#F5F5F5;" | Quantitative/ partial
| align="center" style="background:#F5F5F5;" | 60-70%
| align="center" style="background:#F5F5F5;" | AD
| align="left" style="background:#F5F5F5;" |
* Bleeding severity mild to severe
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" |
|-
|-
! rowspan="4" align="center" style="background:#DCDCDC;" |Type 2
! style=" text-align: left; color: #FFFFFF; background: #4479BA; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |ICU admission
! align="center" style="background:#DCDCDC;" |2A
| style=" text-align: center; color: #FFFFFF; background: #4479BA; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |
| align="center" style="background:#F5F5F5;" | Qualitative
| align="center" style="background:#F5F5F5;" | 10%
| align="center" style="background:#F5F5F5;" | AD/AR
| align="left" style="background:#F5F5F5;" |
* Moderate to severe [[bleeding]]
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" | N or ↓
|-
|-
! align="center" style="background:#DCDCDC;" |2B
! style=" text-align: left; color: #FFFFFF; background: #4479BA; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |Acute stroke on hospitalization
| align="center" style="background:#F5F5F5;" | Qualitative
| style=" text-align: center; color: #FFFFFF; background: #4479BA; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |
| align="center" style="background:#F5F5F5;" | 5%
| align="center" style="background:#F5F5F5;" | AD
| align="left" style="background:#F5F5F5;" |
* [[Thrombocytopenia]]
* Moderate to severe [[bleeding]]
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | N or ↓
|-
|-
! align="center" style="background:#DCDCDC;" |2M
! style=" text-align: left; color: #FFFFFF; background: #4479BA; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |History of VTE
| align="center" style="background:#F5F5F5;" | Qualitative
| style=" text-align: center; color: #FFFFFF; background: #4479BA; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |
| align="center" style="background:#F5F5F5;" | <1%
| align="center" style="background:#F5F5F5;" | AD/AR
| align="left" style="background:#F5F5F5;" |
* Moderate to severe [[bleeding]]
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" | N or ↓
|-
|-
! align="center" style="background:#DCDCDC;" |2N
! colspan="2" style=" text-align: left; color: #4479BA; background: #FFFFFF; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 0 0 rgba(0, 0, 0, 0.2); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |Result:
| align="center" style="background:#F5F5F5;" | Qualitative
| align="center" style="background:#F5F5F5;" | <1%
| align="center" style="background:#F5F5F5;" | AR
| align="left" style="background:#F5F5F5;" |
* Clinically similar to [[hemophilia A]] with [[joint]], [[soft tissue]], [[urinary]] [[bleeding]]
| align="center" style="background:#F5F5F5;" | N
| align="center" style="background:#F5F5F5;" | N
| align="center" style="background:#F5F5F5;" | ↓
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" |Type 3
! colspan="2" style=" text-align: left; color: #4479BA; background: #FFFFFF; padding: 2px 10px; border-radius: 5px 5px 5px 5px; text-shadow: 0 0 0 rgba(0, 0, 0, 0.2); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |Interpretation:  
| align="center" style="background:#F5F5F5;" | Complete deficiency
| align="center" style="background:#F5F5F5;" | 1-2%
| align="center" style="background:#F5F5F5;" | AR
| align="left" style="background:#F5F5F5;" |
* Clinically similar to [[hemophilia A]] with [[joint]] and [[soft tissue]] [[bleeding]]
* Severe [[mucosal bleeding]]
| align="center" style="background:#F5F5F5;" | Absent
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" | Low, 1-10%
|}
|}
For more information on Von Willebrand disease, click [[ von willebrand disease | here]].
<br style="clear:left" />
 
===Interpretation of the Padua Prediction Score===
The interpretation of the score is as follows:
* Score ≥ 4: High risk for VTE
* Score < 4: Low risk for VTE
==References==
<references />
<references />

Latest revision as of 18:11, 14 January 2019


Sandbox: wdx

Xyz

Abc

  1. Sandbox:Preeti
  2. Lymphoma
  3. Breast lumps differential diagnosis
  4. Neck masses differential diagnosis
  5. Leukemia
Category:Risk calculator
Deep vein thrombosis assessment of clinical probability and risk scores
Pulmonary embolism assessment of clinical probability and risk scores
Padua prediction score widget:PaduaVTEscore
IMPROVE risk score calculator Widget:IMPROVEScore
IMPROVEDD risk score calculator Widget:IMPROVEDDScore
Caprini score calculator Widget:CapCal
Wells score calculator for DVT Widget:DVT Wells score calculator
Modified Wells score calculator for DVT Widget:DVT Modified Wells score calculator
Pulmonary embolism Wells score calculator widget:PE_calculator
Pulmonary embolism modified Wells score calculator Widget:PE Modified Wells score calculator
AMUSE score calculator Widget:AMUSE_score_calculator
HAMILTON score calculator Widget:HAMILTON_score_calculator
Geneva score calculator Widget:Geneva_score_calculator
Revised Geneva score calculator Widget:Revised_Geneva_score_calculator
Simplified Geneva Score calculator Widget:Simplified_Geneva_score_calculator
TIMI Risk Score for Unstable Angina or NSTEMI Widget:TIMI_UA_NSTEMI
TIMI Risk Score for STEMI Widget:TIMI_STEMI
Tygerberg score widget:Tygerberg_score
CHA2DS2-VASc Score Widget:CHA2DS2VASc
CHADS2 score Widget:CHADS2score
HAS-BLED score Widget:HASBLEDscore
The GRACE risk score Widget:GRACEscore
Ranson criteria

Acute pancreatitis diagnostic criteria

Widget:RansonScore
Apgar score Widget:Apgarscore
Glasgow coma scale Widget:Adult_GCS
Pediatric Glasgow Coma Scale Widget:PGCS
Cincinnati stroke scale Widget:Cincinnati_Stroke_Scale
DIPSS Plus Score Widget:DIPSS_Plus_Score
ICU scoring systems
APACHE II Widget:APACHEII
SAPS II Widget:SAPSII
SAPS III Widget:SAPSIII
PIM2

Table

Complications Polymyositis Dermatomyositis
Malignancy


Calculation of the Padua Prediction Score

Shown below is a calculator using the predictive score for VTE among hospitalized medical patients. Check all boxes that apply to your patient:

IMPROVE Bleeding Risk Score
Variable Score
Active gastric or duodenal ulcer 4.5
Prior bleeding within the last 3 months 4
Thrombocytopenia (<50x109/L) 4
Age ≥ 85 years 3.5
Liver failure (INR>1.5) 2.5
Severe kidney failure (GFR< 30 mL/min/m2) 2.5
Admission to ICU or CCU 2.5
Central venous catheter 2
Rheumatic disease 2
Active malignancy 2
Age: 40-84 years 1.5
Male 1
Moderate kidney failure (GFR: 30-59 mL/min/m2) 1
Result:
Interpretation:


Calculation of the test Prediction Score

Shown below is a calculator using the predictive score for VTE among hospitalized medical patients. Check all boxes that apply to your patient:

IMPROVE Bleeding Risk Score
Variable Score
Gender Female
Male
Age 0-70
71-80
81-90
>90
Hgb (g/dL) >17 g/dL
15.5-17 g/dL
12.5-15.5 g/dL
12.5-11 g/dL
<11 g/dL
CrCl (mL/min) 30-60 mL/min
15-30 mL/min
Albumin >3.5 g/dL
≤3.5 g/dL
D-dimer ≥1 µg/mL
<1 µg/mL
ICU admission
Acute stroke on hospitalization
History of VTE
Result:
Interpretation:


Interpretation of the Padua Prediction Score

The interpretation of the score is as follows:

  • Score ≥ 4: High risk for VTE
  • Score < 4: Low risk for VTE

References